SGMO icon

Sangamo Therapeutics

0.7870 USD
-0.0279
3.42%
At close Apr 25, 4:00 PM EDT
After hours
0.7900
+0.0030
0.38%
1 day
-3.42%
5 days
10.53%
1 month
-6.22%
3 months
-30.35%
6 months
-47.53%
Year to date
-30.35%
1 year
56.46%
5 years
-90.63%
10 years
-94.10%
 

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Employees: 183

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

30% more capital invested

Capital invested by funds: $48.4M [Q3] → $62.8M (+$14.4M) [Q4]

23% more funds holding

Funds holding: 103 [Q3] → 127 (+24) [Q4]

2.62% more ownership

Funds ownership: 26.86% [Q3] → 29.48% (+2.62%) [Q4]

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

44% less call options, than puts

Call options by funds: $1.87M | Put options by funds: $3.36M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2
154%
upside
Avg. target
$6
662%
upside
High target
$10
1,171%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
21% 1-year accuracy
40 / 187 met price target
1,171%upside
$10
Buy
Reiterated
7 Apr 2025
RBC Capital
Luca Issi
17% 1-year accuracy
9 / 54 met price target
154%upside
$2
Sector Perform
Reiterated
18 Mar 2025

Financial journalist opinion

Positive
Seeking Alpha
3 weeks ago
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Neutral
Business Wire
3 weeks ago
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Neutral
Seeking Alpha
1 month ago
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wainwright Maury Raycroft - Jefferies Nicole Germino - Truist Gena Wang - Barclays Operator Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2024 Teleconference Call.
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.34 per share a year ago.
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results.
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Neutral
Business Wire
2 months ago
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE.
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Neutral
Accesswire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Neutral
Accesswire
2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Neutral
Accesswire
2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Charts implemented using Lightweight Charts™